Is Novo Nordisk Stock a Buy Now?

Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) recently turned a lot of heads with exciting news regarding Wegovy, its anti-obesity treatment.Results of the Steer study showed that treatment with Wegovy reduced patients' risk of heart attack, stroke, or death from any cause by 57%, compared with Eli Lilly's (NYSE: LLY) Zepbound.A big risk reduction is the sort of thing that gets the attention of physicians who must choose between prescribing Wegovy or Zepbound. With this in mind, many investors are assuming the Steer study makes Novo Nordisk a screaming buy right now.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool